Liver injury is the leading cause of drug-induced toxicity. For the evaluation of a chemical compound to induce toxicity, in this case steatosis or fatty liver, it is imperative to identify markers reflective of mechanisms and processes induced upon exposure, as these will be the earliest changes reflective of disease. Therefore, an in vivo mouse toxicogenomics study was completed to identify common pathways, nuclear receptor (NR) binding sites, and genes regulated by three known human steatosis-inducing compounds, amiodarone (AMD), valproic acid (VPA), and tetracycline (TET). Over 1, 4, and 11 days of treatment, AMD induced changes in clinical chemistry parameters and histopathology consistent with steatosis. Common processes and NR binding sites involved in lipid, retinol, and drug metabolism were found for AMD and VPA, but not for TET, which showed no response. Interestingly, the pattern of enrichment of these common pathways and NR binding sites over time was unique to each compound. Eleven biomarkers of steatosis were identified as dose responsive and time sensitive to toxicity for AMD and VPA. Finally, this in vivo mouse study was compared to an AMD rat in vivo, an AMD mouse primary hepatocyte, and a VPA human primary hepatocyte study to identify concordance for steatosis. We conclude that concordance is found on the process level independent of species, model or dose*time point.
Toxicogenomics Hepatotoxicity Steatosis Mouse in vivo In vitro models
This is a preview of subscription content, log in to check access.
The authors wish to thank Dr. E.H. Jansen, P.K. Beekhof, and J. Robinson for performing clinical chemistry and histotechnology procedures, and Dr. I. Tonk for help in the dose response analysis. This work was supported by the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NWO) no: 050-06-510.
Elferink MG, Olinga P, Draaisma AL et al (2008) Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. Toxicol Appl Pharmacol 229(3):300–309PubMedCrossRefGoogle Scholar
Gavrilova O, Haluzik M, Matsusue K et al (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278(36):34268–34276. doi:10.1074/jbc.M300043200PubMedCrossRefGoogle Scholar
Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicological Sciences : An Official Journal of the Society of Toxicology 65(2):166–176CrossRefGoogle Scholar
Kienhuis AS, van de Poll MC, Wortelboer H et al (2009) Parallelogram approach using rat-human in vitro and rat in vivo toxicogenomics predicts acetaminophen-induced hepatotoxicity in humans. Toxicological Sciences : An Official Journal of the Society of Toxicology 107(2):544–552CrossRefGoogle Scholar
Kienhuis AS, Vitins AP, Pennings JL et al (2013) Cyclosporine A treated in vitro models induce cholestasis response through comparison of phenotype-directed gene expression analysis of in vivo Cyclosporine A-induced cholestasis. Toxicol Lett. doi:10.1016/j.toxlet.2013.06.236PubMedGoogle Scholar
Lee MH, Hong I, Kim M et al (2007) Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol Appl Pharmacol 220(1):45–59PubMedCrossRefGoogle Scholar
Lee MH, Kim M, Lee BH et al (2008) Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Toxicol Appl Pharmacol 226(3):271–284PubMedCrossRefGoogle Scholar
McCarthy TC, Pollak PT, Hanniman EA, Sinal CJ (2004) Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. The Journal of pharmacology and experimental therapeutics 311(3):864–873. doi:10.1124/jpet.104.072785PubMedCrossRefGoogle Scholar
Noriyuki N, Igarashi Y, Ono A, Yamada H, Ohno Y, Urushidani T (2012) Evaluation of DNA microarray results in the Toxicogenomics Project (TGP) consortium in Japan. The Journal of toxicological sciences 37(4):791–801PubMedCrossRefGoogle Scholar
Ostapowicz G, Fontana RJ, Schiodt FV et al (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137(12):947–954PubMedCrossRefGoogle Scholar
Rakhshandehroo M, Knoch B, Muller M, Kersten S (2010) Peroxisome proliferator-activated receptor alpha target genes. PPAR research 2010. doi:10.1155/2010/612089
Shu Z, Smith S, Wang L, Rice MC, Kmiec EB (1999) Disruption of muREC2/RAD51L1 in mice results in early embryonic lethality which can Be partially rescued in a p53(-/-) background. Mol Cell Biol 19(12):8686–8693PubMedCentralPubMedGoogle Scholar
van Kesteren PC, Zwart PE, Pennings JL et al (2011) Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53± mice upon exposure to benzo[a]pyrene. Toxicol Sci Off J Soc Toxicol 123(1):123–132. doi:10.1093/toxsci/kfr169CrossRefGoogle Scholar
Yin HQ, Kim M, Kim JH et al (2006) Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. Toxicol Sci Off J Soc Toxicol 94(1):206–216CrossRefGoogle Scholar
Zimmerman HJ (1999) Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, 2nd edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar